Mirzotamab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Mirzotamab Usage And Synthesis

Uses

Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC)[1][2][3].

References

[1] Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021.
[2] Cai Jiaqiang, et al. Antibody-drug conjugate containing BCL-2 family proteolysis agent, preparation method therefor, and use thereof. WO2024153185. 2024.07.25.
[3] Nathanson, David A., et al. Combination therapy for treating glioblastoma. WO2022231996. 2022.11.03.

Mirzotamab(2229859-11-2)Related Product Information

• Tilogotamab
• Fezakinumab
• Benufutamab
• Ligufalimab
• Erfonrilimab
• Astegolimab
• Rivabazumab
• Tafolecimab
• Capromab Pendetide
• Ongericimab